Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue (2015 - 2026)

Arrowhead Pharmaceuticals' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $48.6 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.6 million (changed N/A YoY) and the FY2022 annual result came in at $56.0 million, down 57.45% from the prior year.
• Non-Current Deffered Revenue was $48.6 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $53.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $89.8 million in Q1 2022 and bottomed at $1.1 million in Q1 2023.
• A 4-year average of $51.6 million and a median of $53.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue fell 10.77% — and 2023, when it slumped 98.8%.
• Arrowhead Pharmaceuticals' Non-Current Deffered Revenue stood at $40.8 million in 2022, then sank by 97.36% to $1.1 million in 2023, then surged by 4906.98% to $53.8 million in 2025, then dropped by 9.68% to $48.6 million in 2026.
• Business Quant data shows ARWR's Non-Current Deffered Revenue at $48.6 million in Q1 2026, $53.8 million in Q4 2025, and $1.1 million in Q1 2023.